AAD: Lebrikizumab Shows Efficacy in Skin-of-Color Patients With Atopic Dermatitis
Among patients with atopic dermatitis and self-reported race other than White, 68.3 percent achieved EASI 75 at week 16
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.